Right to Left Cardiac Shunt Detection (PFO Detection)

This study is currently recruiting participants.
Verified December 2013 by Cardiox Corporation
Sponsor:
Information provided by (Responsible Party):
Cardiox Corporation
ClinicalTrials.gov Identifier:
NCT01773252
First received: January 8, 2013
Last updated: December 10, 2013
Last verified: December 2013

January 8, 2013
December 10, 2013
November 2012
July 2014   (final data collection date for primary outcome measure)
  • Presence or absence of shunt [ Time Frame: Five days ] [ Designated as safety issue: No ]
    To establish the sensitivity and specificity of the Cardiox FDS using transesophageal echocardiography (TEE) as the reference standard
  • Adverse Events [ Time Frame: Five days ] [ Designated as safety issue: Yes ]
    To establish the safety of the Cardiox FDS device
Same as current
Complete list of historical versions of study NCT01773252 on ClinicalTrials.gov Archive Site
Presence or absence of shunt [ Time Frame: Three days ] [ Designated as safety issue: No ]
To establish the positive percent agreement and the negative percent agreement of Cardiox FDS procedure with a transcranial Doppler (TCD) from select study sites.
Presence or absence of shunt [ Time Frame: Three days ] [ Designated as safety issue: No ]
To establish the positive percent agreement and the negative percent agreement of Cardiox FDS procedure with transcranial Doppler (TCD).
Not Provided
Not Provided
 
Right to Left Cardiac Shunt Detection
A With-in Subject, Controlled Study to Determine the Sensitivity and Specificity of the Cardiox Flow Detection System for the Detection of Right-to-Left Cardiac Shunts Compared to Transesophageal Echocardiography and Transcranial Doppler Ultrasound

The purpose of this study is to evaluate the sensitivity and specificity of the Cardiox Flow Detection System (FDS) in identifying an intracardiac right-to-left shunt (RLS) compared to the results of transesophageal echocardiography (TEE).

RLS intracardiac shunts are associated with a number of clinically important syndromes including paradoxical thromboembolism (causing stroke or other systemic infarct), migraine headaches (particularly with aura), desaturation with obstructive sleep apnea, and decompression illness. From a research perspective, the detection of shunts in subjects with these types of syndromes is critical in helping to define the role of RLS in these disease processes. From a clinical perspective, shunt detection will be increasingly important in an era where interventional procedures for repairing cardiac defects are available for subjects determined to be at risk.

The currently accepted reference standard for detection of an intra-cardiac patent foramen ovale/atrial septal defect (PFO/ASD) RLS is a transesophageal echocardiography (TEE), a procedure that is invasive, uncomfortable, and requires conscious sedation.

Alternative options include transthoracic echocardiography (TTE) with injection of agitated saline (with and without Valsalva strain), a procedure that is far less sensitive than TEE due to the echocardiography imaging limitations seen in many adults.

Finally, transcranial Doppler (TCD) with injection of agitated saline (with and without Valsalva strain) is a newer entrant into this arena that does not require sedation or any invasive instrumentation.

The Cardiox Model 100 FDS utilizes an optical sensor positioned on the surface of the subject's skin at the scaphoid fossa of the ear. Next, a predetermined dose of an indicator dye, indocyanine green (ICG), is injected at a predetermined rate into a peripheral antecubital vein of the subject while the subject performs a breathing maneuver called a Valsalva maneuver. The exhalation by the subject into a mouthpiece connected to a pressure transducer via a flexible tubing extension, or its equivalent (ie, performing the Valsalva maneuver), is an essential step for all existing RLS detection methods. The Valsalva maneuver by the subject creates a pressure differential between the right and left sides of the heart. This Valsalva maneuver results in blood flow from the right side of the heart to the left side of the heart through an ASD, and/or causes a PFO, if present, to open, also allowing blood to flow directly from the right side to the left side of the heart without passing through the lungs (pulmonary vasculature) for oxygenation.

The Earpads, including their fluorescence sensor arrays (FSA), are used to measure the relative concentration (ie, fluorescence signal level) of ICG dye in the bloodstream as a function of time. If a premature inflection or peak occurs in the ICG dye concentration level at a time point prior to the rise and fall of the concentration associated with the main bolus of indicator, then a RLS is present in the heart. The amplitude of this premature ICG dye-dilution curve (referred to as "RLS-indicator dilution curve") is used to subsequently quantify the magnitude of the right-to-left shunt by ratiometrically comparing the amplitude of this RLS indicator dilution curve to the amplitude of the main indicator dilution curve associated with that portion of the injected ICG dye that follows the normal pathway from the right side of the heart, through the lungs, and into the left side of the heart (referred to as "normal indicator dilution curve").

Not Provided
Interventional
Phase 3
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Diagnostic
  • Right to Left Shunt
  • Patent Foramen Ovale
  • Atrial Septal Defect
Device: Flow Detection System
Other Name: Model 100
Experimental: TEE
Within patient comparison of TEE, FDS and a TCD from select study sites
Intervention: Device: Flow Detection System
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
150
July 2014
July 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • At least 18 years of age;
  • Is currently scheduled (within five days of FDS) for a TEE study with agitated saline contrast (bubble study) or has had a TEE procedure with agitated saline contrast study (bubble study) within the previous 12 months;
  • If the Subject has undergone a shunt closure procedure, the protocol related TEE must be conducted greater than 12 months post closure.
  • Is able to read and understand the ICF and has voluntarily provided written informed consent;
  • Subject is able to perform a successful Valsalva maneuver (obtaining a score of 3 stars) using the Cardiox FDS device.

Exclusion Criteria:

  • Subjects with known allergy or sensitivity to ICG or to iodide contrast dye or iodides including medications with high iodine content;
  • Pregnant women or nursing mothers;
  • Subjects scheduled for a radioactive iodine uptake studies (eg, thyroid studies) within one week of completing this study.
Both
18 Years and older
No
Not Provided
United States
 
NCT01773252
FDS-0005
No
Cardiox Corporation
Cardiox Corporation
Not Provided
Not Provided
Cardiox Corporation
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP